BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/11/2015 4:38:00 PM | Browse: 1039 | Download: 1359
Publication Name World Journal of Gastroenterology
Manuscript ID 12394
Country Spain
Received
2014-07-06 14:01
Peer-Review Started
2014-07-07 12:09
To Make the First Decision
2014-08-06 17:16
Return for Revision
2014-08-14 13:43
Revised
2014-09-21 17:09
Second Decision
2014-11-11 10:07
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-11-11 10:23
Articles in Press
2014-11-11 10:59
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2015-02-03 16:53
Publish the Manuscript Online
2015-02-11 16:38
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Letter to the Editor
Article Title Adalimumab-induced interstitial pneumonia in a patient with Crohn’s disease
Manuscript Source Unsolicited Manuscript
All Author List María José Casanova, María Chaparro, Claudia Valenzuela, Carolina Cisneros and Javier P Gisbert
Funding Agency and Grant Number
Funding Agency Grant Number
CIBEREHD is founded by Instituto de Salud Carlos III
Corresponding Author María José Casanova, MD, PhD, Gastroenterology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IP), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Canillas, 70 2º-G, CP 28002 Madrid, Spain. mjcasanova.g@gmail.com
Key Words Adalimumab; Anti-tumor necrosis factor; Crohn’s disease; Interstitial pneumonia
Core Tip Lung injury secondary to anti-tumor necrosis factor (TNF) drugs could cause severe respiratory symptoms in patients exposed to this therapy, and it should be suspected in patients who: have a temporal association between the onset of respiratory symptoms and the exposure to anti-TNF drugs, show a compatible pattern in the biopsy, and offer negative results for infection. There are a few cases reported of adalimumab-lung toxicity in patients with inflammatory bowel disease. Clinical improvement after biologic therapy discontinuation strongly supports the diagnosis. The mechanism by which anti-TNF drugs induce lung injury remains unclear; therefore, the use of another anti-TNF drug should be discouraged.
Publish Date 2015-02-11 16:38
Citation Casanova MJ, Chaparro M, Valenzuela C, Cisneros C, Gisbert JP. Adalimumab-induced interstitial pneumonia in a patient with Crohn’s disease. World J Gastroenterol 2015; 21(7): 2260-2262
URL http://www.wjgnet.com/1007-9327/full/v21/i7/2260.htm
DOI http://dx.doi.org/10.3748/wjg.v21.i7.2260
Full Article (PDF) WJG-21-2260.pdf
Full Article (Word) WJG-21-2260.doc
Manuscript File 12394-Review.doc
Answering Reviewers 12394-Answering reviewers.pdf
Copyright License Agreement 12394-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate 12394-Language certificate.pdf
Peer-review Report 12394-Peer reviews.pdf
Scientific Misconduct Check 12394-CrossCheck.jpg
Scientific Editor Work List 12394-Scientific editor work list.pdf